Equities Analysts Offer Predictions for LENZ Q1 Earnings

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Stock analysts at William Blair cut their Q1 2025 earnings per share (EPS) estimates for shares of LENZ Therapeutics in a research report issued to clients and investors on Thursday, March 20th. William Blair analyst L. Hanbury-Brown now forecasts that the company will earn ($0.56) per share for the quarter, down from their previous forecast of ($0.48). The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($2.18) per share. William Blair also issued estimates for LENZ Therapeutics’ Q3 2025 earnings at ($0.74) EPS, Q4 2025 earnings at ($0.98) EPS, FY2025 earnings at ($2.97) EPS, Q1 2026 earnings at ($0.92) EPS, Q2 2026 earnings at ($0.77) EPS, Q3 2026 earnings at ($0.67) EPS and Q4 2026 earnings at ($0.53) EPS.

LENZ Therapeutics (NASDAQ:LENZ) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.04).

Several other equities analysts also recently commented on LENZ. Citigroup upped their price objective on shares of LENZ Therapeutics from $44.00 to $47.00 and gave the company a “buy” rating in a research note on Thursday, March 20th. TD Cowen began coverage on LENZ Therapeutics in a research report on Tuesday, March 18th. They set a “buy” rating and a $60.00 price target for the company. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, LENZ Therapeutics has an average rating of “Buy” and an average price target of $41.67.

LENZ Therapeutics Stock Up 0.6 %

NASDAQ:LENZ opened at $26.66 on Monday. The firm has a market capitalization of $733.18 million, a P/E ratio of -5.59 and a beta of 0.58. LENZ Therapeutics has a 52 week low of $14.42 and a 52 week high of $38.93. The company has a fifty day moving average of $24.22 and a 200 day moving average of $27.10.

Hedge Funds Weigh In On LENZ Therapeutics

A number of institutional investors have recently bought and sold shares of LENZ. Wellington Management Group LLP boosted its position in LENZ Therapeutics by 14.6% during the 4th quarter. Wellington Management Group LLP now owns 28,216 shares of the company’s stock valued at $815,000 after acquiring an additional 3,595 shares in the last quarter. California State Teachers Retirement System boosted its position in shares of LENZ Therapeutics by 911.0% during the fourth quarter. California State Teachers Retirement System now owns 9,200 shares of the company’s stock valued at $266,000 after purchasing an additional 8,290 shares in the last quarter. Delta Investment Management LLC purchased a new stake in LENZ Therapeutics in the fourth quarter worth $555,000. Rafferty Asset Management LLC bought a new position in LENZ Therapeutics in the fourth quarter worth $511,000. Finally, Paradigm Biocapital Advisors LP bought a new position in LENZ Therapeutics in the fourth quarter worth $22,243,000. 54.32% of the stock is owned by institutional investors.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.